Conversely, the blockade of TNFα signaling, either via antibody neutralization or through receptor deficiency, was sufficient to reduce the expression of pro-inflammatory surface markers and promote the gain of a pro-resolving phenotype both ex vivo and in CGD mice in vivo. The gene discussed is TNF; the disease is chronic granulomatous disease.